1. Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.
- Author
-
Arahata M, Takamatsu H, Morishita E, Kadohira Y, Yamada S, Ichinose A, and Asakura H
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Immunoglobulin Light-chain Amyloidosis complications, Male, Middle Aged, Treatment Outcome, Blood Coagulation, Fibrinolysis, Hemorrhage drug therapy, Hemorrhage etiology, Immunoglobulin Light-chain Amyloidosis blood, Tranexamic Acid therapeutic use
- Abstract
Abnormal bleeding is sometimes observed in patients with immunoglobulin light chain (AL) amyloidosis. Although several theories have been proposed regarding the pathological causes of the bleeding tendency in AL amyloidosis, many lacked sufficient evidence and full consensus. We conducted a retrospective survey at a single institution to assess bleeding manifestations, methods for evaluating hematological abnormalities, and treatments for bleeding in patients with systemic AL amyloidosis over the past 13 years. The participants were 10 men and 14 women, aged 39-84 years (mean 65 years). The prevalence of bleeding was 29%. Prolonged prothrombin time (PT), elevated plasmin-α2-antiplasmin complex, and factor X deficiency were distinctive to the bleeding group. Two case studies showed that tranexamic acid was effective for treating this hematological condition. However, two patients with normal PT and activated partial thromboplastin time (APTT) also had a bleeding manifestation. The rates of administration of coagulation and fibrinolytic tests were relatively low in the non-bleeding group. Therefore, a close investigation concerning coagulation and fibrinolysis should be performed in every patient with AL amyloidosis regardless of the PT/APTT values. A more careful, comprehensive, and large-scale study is required to reinforce these findings.
- Published
- 2020
- Full Text
- View/download PDF